Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) Operating Margin (2020 - 2025)

Pliant Therapeutics (PLRX) has disclosed Operating Margin for 5 consecutive years, with 17336.03% as the latest value for Q4 2025.

  • On a quarterly basis, Operating Margin changed N/A to 17336.03% in Q4 2025 year-over-year; TTM through Dec 2025 was 6110.71%, a N/A change, with the full-year FY2023 number at 11654.75%, down 1034138.0% from a year prior.
  • Operating Margin was 17336.03% for Q4 2025 at Pliant Therapeutics, up from 3468.59% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 17336.03% in Q4 2025 to a low of 19083.87% in Q2 2023.
  • A 4-year average of 42.81% and a median of 1255.42% in 2021 define the central range for Operating Margin.
  • Peak YoY movement for Operating Margin: soared 68612bps in 2022, then plummeted -1848972bps in 2023.
  • Pliant Therapeutics' Operating Margin stood at 1230.57% in 2021, then crashed by -55bps to 1903.31% in 2022, then plummeted by -903bps to 19083.87% in 2023, then surged by 191bps to 17336.03% in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Operating Margin are 17336.03% (Q4 2025), 3468.59% (Q3 2025), and 5635.6% (Q2 2025).